No Prescription |
 |
 | ||
|
Tacrograf Prograf |
|
| ||
No Prescription » Prescription Drugs 15 » Tacrograf Prograf Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney liver or heart transplants. Tacrolimus is in a class of medications called immunosupressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. Buy Tacrograf Prograf and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Tacrograf Prograf: Product Type: Prescription Drugs 15 Tacrograf (Prograf Generic Tacrolimus) Tacrograf (Prograf Generic Tacrolimus) Prograf Generic Tacrolimus 0.5mg 100 Tablets 0.5mg 200(2 x 100) Tablets 0.5mg 300(3 x 100) Tablets 2mg 100 Tablets 2mg 200(2 x 100) Tablets 3mg 100 Tablets 3mg 200(2 x 100) Tablets 5mg 100 Tablets Prograf Generic Tacrolimus Tacrograf
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
